Rhinomed News

Rhinoswab Detects SARS-CoV-2 in Doherty Institute rt-PCR STudy

Rhinomed is pleased to report positive data from its lab-based spiking study of Rhinomed’s new Rhinoswab conducted at the Victorian Infectious Diseases Reference Laboratory (VIDRL), part of The Peter Doherty Institute for Infection and Immunity (The Doherty) in Melbourne. The study’s objective was to demonstrate efficacy in detecting the SARS-CoV-2 virus at both low and … Read more

Rhinomed’s New High Comfort Nasal Swab Successfully Registered With Australian TGA

Rhinomed has successfully registered its easy to use, high load capturing, comfortable nasal swab with the Australian Therapeutic Goods Administration (TGA) as a Class 1 device. The new swab can comfortably collect samples from both nostrils simultaneously to test for the presence of upper respiratory tract diseases including influenza and coronavirus including SARS-CoV-2. The unique … Read more

Nasal swab Registered With US FDA

Rhinomed Limited is pleased to announce that it has successfully registered its novel nasal swab with the US FDA as a Class 1 device to collect samples from the nose to detect upper respiratory tract diseases including influenza and coronavirus strains. The successful registration and conformity with the relevant standards means that Rhinomed’s novel nasal … Read more

Rhinomed Developing New Nasal Swab

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in nasal airway and respiratory technology, is advanced in developing a new high-yielding nasal swab that can collect samples from the nose to test for the presence of upper respiratory tract diseases, including influenza and coronavirus strains. Read a full copy of the report here.

Rhinomed Records Positive Year On Year Result

Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, can report its FY 20 Q4 results and preliminary unaudited full year results. After a record FY20 Q3 result the company was on track to reach its full year planned targets. Confirmation during the quarter that … Read more

Rhinomed Delivers Major Milestone: Pronto to Appear in 6,336 New Stores in US

Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, today announces it has received purchase orders confirming a major distribution expansion of its Pronto Clear nasal decongestion technology within one of the largest and leading pharmacy and drugstore chains in the USA. Read a full … Read more

RNO Signs 12 Year Licensing Agreement With USA’s Largest Medical Cannabis Operator

Rhinomed (ASX:RNO) is pleased to advise investors it has signed a 12-year exclusive licensing agreement of its nasal platform technology with Columbia Care LLC, the largest and most experienced provider of cannabis-based products and services in the United States (U.S.). Read a full copy of the report here.

New Retailer to Stock Mute in 3000 New USA Pharmacies

NEW RETAILER TO STOCK MUTE IN 3000 NEW USA PHARMACIES May 28 2018, ​ Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise investors that it has entered into a new distribution agreement with, and received an initial order for stock from a new retailer. The retailer is one of America’s largest … Read more

Rhinomed​ to Present at International Investor Conferences

RHINOMED​ ​TO PRESENT AT INTERNATIONAL INVESTOR CONFERENCES March 5, 2018.​ Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise it will exhibit and present at two major investor conferences in the USA and the UK in March. Read a full copy of the announcement here.

Rhinomed​ ​Change in Executive Remuneration

March 2, 2018.​ Melbourne, Australia.Rhinomed (ASX:RNO or “the Company) engaged Crichton and Associates, remuneration consultants to review its remuneration policies and make recommendations on the Company’s remuneration levels based on the market conditions and expectations. Read a full copy of the announcement here.

Rhinomed​ ​Completes AUD $3.6M Capital Raise

Rhinomed Limited (ASX: RNO or “the Company”) a leading sleep and nasal respiratory technology company has successfully undertaken an AUD$3.6 million placement to institutional and sophisticated private investors at $0.15 per share. Read a full copy of the announcement here.

LEADING WHOLESALER PHOENIX HEALTHCARE TO WHOLESALE MUTE IN UK

LEADING WHOLESALER PHOENIX HEALTHCARE TO WHOLESALE MUTE IN UK   October 31, 2017.​ Melbourne, Australia. Nasal respiratory technology company Rhinomed (ASX:RNO) is pleased to announce a wholesale distribution agreement with UK based Phoenix Healthcare Distribution Limited.   Under the agreement, all four SKU’s (Trial pack and three sized packs) of Mute will be available for ordering … Read more